GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » YIFAN PHARMACEUTICAL CO LTD (SZSE:002019) » Definitions » Price-to-Owner-Earnings

YIFAN PHARMACEUTICAL CO (SZSE:002019) Price-to-Owner-Earnings : (As of May. 26, 2024)


View and export this data going back to 2004. Start your Free Trial

What is YIFAN PHARMACEUTICAL CO Price-to-Owner-Earnings?

As of today (2024-05-26), YIFAN PHARMACEUTICAL CO's share price is ¥13.51. YIFAN PHARMACEUTICAL CO does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for YIFAN PHARMACEUTICAL CO's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of YIFAN PHARMACEUTICAL CO was 227.50. The lowest was 12.17. And the median was 45.49.


SZSE:002019's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 27.13
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-26), YIFAN PHARMACEUTICAL CO's share price is ¥13.51. YIFAN PHARMACEUTICAL CO's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-0.38. Therefore, YIFAN PHARMACEUTICAL CO's PE Ratio for today is At Loss.

As of today (2024-05-26), YIFAN PHARMACEUTICAL CO's share price is ¥13.51. YIFAN PHARMACEUTICAL CO's EPS without NRI for the trailing twelve months (TTM) ended in was ¥0.39. Therefore, YIFAN PHARMACEUTICAL CO's PE Ratio without NRI for today is 35.00.

During the past 13 years, YIFAN PHARMACEUTICAL CO's highest PE Ratio without NRI was 91.65. The lowest was 9.59. And the median was 30.08.


YIFAN PHARMACEUTICAL CO Price-to-Owner-Earnings Historical Data

The historical data trend for YIFAN PHARMACEUTICAL CO's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

YIFAN PHARMACEUTICAL CO Price-to-Owner-Earnings Chart

YIFAN PHARMACEUTICAL CO Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.16 54.09 - - -

YIFAN PHARMACEUTICAL CO Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of YIFAN PHARMACEUTICAL CO's Price-to-Owner-Earnings

For the Drug Manufacturers - General subindustry, YIFAN PHARMACEUTICAL CO's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


YIFAN PHARMACEUTICAL CO's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, YIFAN PHARMACEUTICAL CO's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where YIFAN PHARMACEUTICAL CO's Price-to-Owner-Earnings falls into.



YIFAN PHARMACEUTICAL CO Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

YIFAN PHARMACEUTICAL CO's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=13.51/-0.85
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


YIFAN PHARMACEUTICAL CO  (SZSE:002019) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


YIFAN PHARMACEUTICAL CO Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of YIFAN PHARMACEUTICAL CO's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


YIFAN PHARMACEUTICAL CO (SZSE:002019) Business Description

Traded in Other Exchanges
N/A
Address
No. 50 Qinshan, Jincheng, Lin'an Economic Development Zone, Hangzhou, Zhejiang, CHN, 311300
YIFAN PHARMACEUTICAL CO LTD is a China-based company engaged in pharmaceutical innovation and manufacturing. The company focuses its activities on key areas like macromolecular biologics, high-value pharmaceuticals, and differentiated traditional Chinese medicines. The products of the company are F-627 for Neutropenia and Parkinson's disease, F-652 for acute alcoholic hepatitis, GvHD and acute pancreatitis and F-899 for growth deficiency. The company's products are sold in China and internationally.
Executives
Ye Yi Qun Director
Zhang Da Wei Executives
Geng Yu Hong Executives
Feng De Qi Directors, Directors, and Executives
Zhou Ben Yu Director
Lin Xing Directors, executives
Yu Hai Xia Executives
Cheng Xian Feng Directors, executives
Xu Guo Han Supervisors
Cao Shi Mei Director
Lin Guan Yu Director
Zhang Lian Chun Executives
Guo Xin Fu Director
Zheng Shi Ming Supervisors
Yin Hang Hua Executives

YIFAN PHARMACEUTICAL CO (SZSE:002019) Headlines

No Headlines